INTRODUCTION
Antitumor therapies frequently induce shrinkage of tumor mass, but a population of cells will almost invariably survive therapy. The selective pressure of therapy can lead to the development of resistance in this population, which may subsequently grow out into a clinically important tumor burden. Given the continued importance of chemotherapy in cancer management, chemoresistance is a major hurdle in effective anticancer treatment. Strategies to overcome this will thus have a significant impact on treatment outcome.
Drug resistance is generally considered to be evoked by altered intrinsic or acquired pathways within tumor cells. However, accumulating evidence suggests that antitumor therapies, in addition to their direct cytotoxic effects on tumor cells, also induce a systemic host response, which plays a role in therapy resistance. Here, we summarize the available literature on how anticancer drugs activate host responses to the unfortunate benefit of tumors, and provide a perspective on how to exploit these host responses to improve therapy effectiveness.
Host-tumor interactions Solid tumors consist of cancer cells surrounded by a microenvironment containing non-neoplastic stromal cells, blood vessels and the extracellular matrix. 1 Tumors avidly interact with their microenvironment, not only following antitumor therapies but in all stages of tumor growth and development. In the absence of therapy, bone marrow-derived progenitor cells, immune cells and cells forming and supporting blood vessels are actively recruited by the tumor. 2, 3 These recruited cells in the microenvironment can collaborate with the neoplastic cancer cells to promote tumor growth and metastatic spread. [4] [5] [6] For example, cancer-associated fibroblasts have been shown to express a proinflammatory signature in tumors, which triggers tumor growth and angiogenesis. 7 Reciprocal interactions between tumor cells and surrounding cells can protect the tumor cells against therapy-induced cell death. 8 A number of mechanisms have been described. First, protective niches for tumor cells are created through enhanced tumor cell adhesion to microenvironment components and by secretion of soluble factors. [9] [10] [11] [12] The bone marrow forms such a niche for tumor cells, among others by secretion of factors such as SDF-1, the ligand of CXCR-4, which attracts tumor cells to the bone marrow and stimulates their survival. IL-6 secretion can activate anti-apoptotic JAK and BCL-XL signaling in the tumor cells, protecting them from apoptosis. 13 Second, non-neoplastic cells can trigger tumor cells to convert to phenotypes rendering them less sensitive to therapy, such as epithelial-to-mesenchymal transition, a stem cell-like state or senescence. [14] [15] [16] [17] [18] [19] Finally, the microenvironment can provide a physical barrier limiting drug penetration in the tumor. Aberrant tumor blood vessels that cause high interstitial pressure, impaired blood flow and subsequent hypoxia can reduce drug concentration in the tumor. 20 Alternatively, in pancreatic cancer, the highly desmoplastic stromal compartment limits drug access to the tumor. 21, 22 The importance of tumor-stroma interactions as determinants of therapy response is demonstrated by the observation that removal of the microenvironment often restores tumor cell sensitivity. 8 Multiple studies have shown that acquired in-vivo resistance can occur without altering intrinsic tumor cell sensitivity, [23] [24] [25] and the in-vivo effectiveness, or lack thereof, of cytotoxic agents is hard to recapitulate in ex-vivo assays. 26 In cancer patients, specific properties of stromal cells can even be an indicator of poor prognosis. For instance, increased stromal gene expression predicts resistance to preoperative chemotherapy in breast cancer patients.
The most publicized example of a combination of chemotherapy with drugs specifically targeting the tumor microenvironment is the use of antiangiogenic agents such as bevacizumab, an antibody directed against vascular endothelial growth factor (VEGF). A number of other drugs targeting non-neoplastic cells surrounding the tumor are in clinical development, such as VLA-4 inhibitors 28 and hedgehog inhibitors. 29 However, this last class of agents exemplifies that the development of combinatorial approaches may be challenging: the elegant preclinical studies showing that a blockade of hedgehog signaling augments gemcitabine efficacy in pancreatic tumors in mice were not confirmed in a subsequent clinical study. 21, 30 Finally, agents initially developed to target tumor cells also affect the microenvironment. Tyrosine kinase inhibitor erlotinib, which targets tumor cells overexpressing EGFR, was shown to modulate tumor-stroma interactions. 31 Similarly, imatinib, commonly used for its specificity against the Bcr-Abl fusion protein and in the treatment of tumors overexpressing c-kit, can inhibit stromal cell functions. [32] [33] [34] The efficacy of these agents might be partially due to their effects on the microenvironment.
Impact of chemotherapy on host-tumor interactions: 'the host response' Even though chemotherapy was designed to target rapidly dividing tumor cells, systemic administration of a cytotoxic agent will invariably hit non-neoplastic cells as well. Acute side effects such as mucositis, myelosuppression and hair loss have taught us early on that proliferating and rapidly regenerating healthy tissues are damaged: the lining of the gut, the bone marrow and hairfollicle cells. A number of recent studies show that chemotherapy also has impact on multiple cell types in the tumor microenvironment. In some cases, the effects of chemotherapy on healthy tissues may enhance treatment benefits. For instance, conventional cytotoxic agents have been shown to target proliferating endothelial cells of the growing tumor vasculature, thereby diminishing angiogenesis. These antiangiogenic effects of chemotherapy can be optimized by prolonged administration of lowdose chemotherapy without drug-free breaks, the so-called 'metronomic' regimen. [35] [36] [37] [38] Furthermore, some chemotherapeutic agents were shown to have immunogenic effects that enhance their anticancer efficacy, for example, suppression of protumorigenic regulatory T cells by low-dose cyclophosphamide. 39 Other examples include selective cytotoxicity towards tumor-associated myeloidderived suppressor cells by 5-FU, 40 and the activation of tumor antigen-specific T-cell immunity due to release of HMGB1 by dying tumor cells following anthracycline-based chemotherapy. 41 On the contrary, gemcitabine and 5-FU were recently shown to induce MDSC-mediated T-cell proliferation into IL-17-producing CD4 þ T cells able to reduce chemotherapy efficacy. 42 Thus, in addition to the beneficial effects on the microenvironment, chemotherapy may also induce a host response with a 'malignant' character ( Figure 1 ). Theoretically, this could lead to the paradoxical situation where treatment effects of an anticancer drug on the microenvironment impair its activity on the tumor.
Bone marrow-derived cells in the host response To study the consequences of the host response on tumor growth, one has to distinguish these effects from the potent, direct antitumor effects of cytotoxic agents. Administration of chemotherapy to non-tumor-bearing mice provides an elegant solution to this challenge. Using plasma from non-tumor-bearing mice that had been treated with paclitaxel, Gingis-Velitsky et al. 43 found enhanced migration and invasion of tumor cells in vitro. Additionally, an increased number of bone marrow cells expressing MMP-9 was observed in paclitaxel-treated tumors, which enhanced tumor cell dissemination via an epithelialto-mesenchymal transition process, thereby accelerating metastatic spread. 43 Paclitaxel administration to non-tumorbearing mice also elevated plasma levels of SDF-1, the ligand of CXCR-4, which mobilized circulating endothelial progenitor cells (CEPs) from the bone marrow into the circulation. Interestingly, also in patients that received taxanes as adjuvant therapy, elevations in SDF-1 and CEPs were found. 44 When paclitaxel was administered to tumor-bearing mice, mobilized CEPs were shown to home to the tumor microenvironment, where they contributed to angiogenesis and subsequent primary tumor regrowth. 45 Antibodies neutralizing SDF-1 or VEGF-A blocked the rapid CEP mobilization and augmented taxane activity, thus providing an example of how interference with the host response can enhance therapy efficacy.
In addition to CEPs, chemotherapy also enhanced tumor colonization of other types of pro-angiogenic bone marrow-derived cells (BMDCs), such as hemangiocytes and Tie2-expressing monocytes. [45] [46] [47] Two populations of Notch-expressing cells with endothelial cell-like and monocyte-like characteristics were recruited to tumors upon exposure to chemotherapy. Both cell types, which were derived from VE-cadherin-expressing cells in the bone marrow, induced acquired therapy resistance that could be suppressed by inhibiting Notch. 48 Finally, two research groups showed that paclitaxel attracts tumor-associated macrophages (TAMs) to mammary tumors. Shree et al. 49 showed that TAMs interfered with the response to chemotherapy by secretion of cathepsins. Concurrent therapy with paclitaxel and cathepsin inhibitors slowed tumor growth, which was even more effective when low-dose metronomic chemotherapy was added to this regimen. 49 Importantly, work by De Nardo et al. 50 suggests that the homing of TAMs to tumors might actually be a tumor response instead of a host response, as they found that chemotherapy mediated production of CSF1 in tumors (and not in host cells), which then resulted in recruitment of host-derived TAMs. Blocking CSF1/ CSF1R signaling depleted TAMs from tumors, and the combination of paclitaxel with an agent interfering with CSF1/CSF1R enhanced primary tumor response and decreased metastatic spread. 50 Other anticancer therapies also induce host responses involving bone marrow-derived cells, suggesting that this is a more general phenomenon not limited to chemotherapy. Antiangiogenic receptor tyrosine kinase inhibitor (RTKI) therapy results in changes in (among others) VEGF and sVEGFR-2 plasma levels in both preclinical and clinical studies. [51] [52] [53] [54] [55] [56] Following RTKI therapy, tumor colonization of Tie2-expressing monocytes, TAMs and myeloidderived suppressor cells was seen, [57] [58] [59] [60] and the upregulation of several redundant pro-angiogenic pathways in the microenvironment following VEGF-A blockade can be considered a host response to therapy. 61 Furthermore, administration of vascular disrupting agents, cytotoxic-like drugs that target the established but abnormal tumor vasculature, resulted in the mobilization and subsequent recruitment of CEPs and Tie2-expressing monocytes to tumors by mechanisms quite similar to taxane therapy. [62] [63] [64] [65] [66] Surgical interventions are dependent on physiological tissue repair, which in certain situations may also support tumor survival. Elevated levels of CEPs and other BMDCs have been shown in response to open abdominal surgery when compared with laparoscopy, [67] [68] [69] in theory supporting less invasive surgery. Finally, low-dose irradiation is known to affect endothelial cells and angiogenesis, potentially promoting tumor outgrowth. 70 More aggressive tumors were observed in mice that had been irradiated prior to tumor cell implantation. 71 Radiotherapy was also shown to attract myeloid cells and mesenchymal stem cells (MSCs) to treated tumors, even though it remains to be determined whether this is solely due to a host response, or that a tumor responsehas a role here as well. 72, 73 Overall, these findings suggest that multiple types of anticancer therapy affect the tumor microenvironment, which can promote outgrowth and repopulation of treated tumors.
Even in the absence of therapy, enhanced numbers of MSCs are present in the circulation of cancer patients. 74, 75 These circulating MSCs take part in the host response to chemotherapy. In preclinical mouse models, administration of platinum chemotherapy was able to activate circulating MSCs, which then secreted factors that protected the tumor against chemotherapy. These factors were identified as the rare, largely unknown fatty acids hexadeca-4,7,10,13-tetraenoic acid (16-4(n-3)) and 12-oxo-5,8,10-heptadecatrienoic acid (KHT). Their secretion in response to platinum exposure resulted in the designation 'PIFAs': platinum-induced fatty acids. Both PIFAs were produced downstream of COX-1 and thromboxane synthase, and inhibition of either of these enzymes was able to prevent PIFA secretion from MSCs. Combining cisplatin with inhibitors of COX-1 or thromboxane synthase augmented antitumor efficacy compared with cisplatin alone. 75 These findings may have clinical consequences because platinum compounds were also found to activate MSCs derived from healthy volunteers to secrete PIFAs, which then induced chemoresistance in xenografts. Moreover, as PIFAs were shown to protect tumors against a broad spectrum of chemotherapeutic agents, this type of resistance might not be limited to platinum monotherapy, but could also affect platinumcontaining combination chemotherapy. This supports clinical exploration of the combination of chemotherapy with inhibitors of COX-1 and thromboxane synthase.
Non-bone marrow-derived cells in the host response The majority of cells in the tumor microenvironment are fibroblast-like cells, 5 which partially originate from MSCs and contribute to tumor progression. 76 Sun et al. 77 analyzed DNA damage in fibroblasts in tissues from prostate, breast and ovarian cancer patients after chemotherapy. Extensive DNA damage and subsequent NF-kB activation occured, resulting in a 'DNA damage secretory program' (DDSP). Numerous growth factors and cytokines were secreted by fibroblasts ensuing chemotherapyinduced damage, among which was WNT16B, promoting phenotypic changes in tumor cells through paracrine mechanisms. Not only tumor cell proliferation, epithelialto-mesenchymal transition, migration and invasion were enhanced, but response to cytotoxic therapy was impaired as well. Blocking the DDSP through either NF-kB or WNT16B attenuation restored tumor response to chemotherapy. 77 Some aspects of the host response to chemotherapy are tissuespecific. Gilbert et al. 78 reported a thymus-specific response to cytotoxic drugs that impaired tumor regression specifically at that anatomical localization. In a mouse model of disseminated Burkitt's lymphoma, doxorubicin exposure resulted in tumor regression at all lymphoid tissues with the exception of the thymus. There, minimal residual disease remained from which tumors regrew. Cytotoxic agents were shown to activate stressresponsive kinases such as p38-MAPK in endothelial cells in the thymic microenvironment, which resulted in the secretion of soluble factors from endothelial cells. These factors, for example, IL-6 and TIMP-1, subsequently protected tumor cells against genotoxic chemotherapy.
Even though the nature of the secreted factors differ, the results obtained by Roodhart et Figure 1 . Various aspects of the host response to antitumor therapy may interfere with treatment outcome. The host response includes upregulation of cytokines, followed by the acute mobilization and tumor homing of pro-angiogenic BMDCs. Activation of cells in the tumor microenvironment takes place, resulting in production of systemic or paracrine factors. Furthermore, tissue-specific responses to chemotherapy in lungs and thymus can provide a protective niche to tumor cells. CEP, circulating endothelial progenitor cell; TEM, Tie2-expressing monocyte; BMDC, bone marrow-derived cell; MSC, mesenchymal stem cell; PIFA, platinum-induced fatty acid; SDF-1, stromal cellderived factor 1; VEGF, vascular endothelial growth factor; G-CSF, granulocyte colony-stimulating factor; VEGFR-1, vascular endothelial growth factor receptor 1; IL-6, interleukin-6; TIMP-1, tissue inhibitor of metalloproteinase 1; DDSP, DNA damage secretory program; MMP-9, matrix metallopeptidase 9; MDSC, myeloid-derived suppressor cell; T H 17, T helper cell type 17; IL-1b, interleukin-1b; IL-17, interleukin-17.
'senescence-associated secretory phenotype' 80 or 'senescence messaging secretome' 82 is usually observed a few days after DNA damage. 81 The thymic response to doxorubicin is in fact accompanied by a gradually occurring, temporary senescent state of the thymic tissue. 78 However, IL-6 production already occurs within 18 h of chemotherapy treatment, much more acute than the senescent phenotype. The PIFA response is even faster: one gift of chemotherapy can release PIFAs from MSCs, which can then protect against the antitumor effects of this same gift of chemotherapy. Hence, a full-blown senescent state is not required to induce the host response, but initial cell stress or damage may be the triggers. In addition, a number of controversial studies have shown that oxidative stress can drive autophagy in cancer-associated fibroblasts, resulting in increased availability of nutrients to stimulate cancer cell metabolism. This process is known as the 'Reverse Warburg Effect'. 83 Finally, another 'tissue-specific survival niche' can be found in the pulmonary vascular bed. When chemotherapy was administered to non-tumor-bearing mice followed by i.v. tumor cell injection, the number of pulmonary tumor cell colonies was enhanced compared with mice without pretreatment. 43, [84] [85] [86] [87] Priming of the lungs by chemotherapy was recently shown to induce VEGFR-1 upregulation on a specific population of pulmonary endothelial cells, resulting in enhanced tumor cell retention in the lungs by a not yet uncovered mechanism. Combining chemotherapy with an antibody targeting VEGFR-1 diminished early retention of tumor cells in the lungs and prevented formation of chemotherapy-induced metastases. Thus, when the direct antitumor effects of chemotherapy were absent, the host response could be visualized, creating an environment favorable for tumor-cell colonization by directly affecting lung endothelial cells and priming the lung for tumor cell colonization. 88 We believe that by uncovering the host response that is usually masked by the potent antitumor activity of the chemotherapy drugs, this model shows a 'proof of concept'. It is likely that the effects of the drug on the microenvironment are also present when treating an in-situ tumor. In the physiological situation (that is, in the presence of direct effects on tumor cells), the prosurvival response of the microenvironment may limit the antitumor efficacy of the drug. As preclinical studies showed similar effects following pretreatment with RTKIs such as sunitinib, 89 the host response might provide a general explanation for the lack of prolonged therapy effectiveness in patients, as well as a target for enhanced tumor control.
Exploiting the host response to enhance chemotherapy efficacy How can we now use the knowledge gained in these studies to optimize patient therapy? Although maximum-tolerated dose chemotherapy has clear benefits, one option is to change timing and dosing of chemotherapy. Current chemotherapy regimens are given in multiple doses with long drug-free breaks in between to allow recovery of normal tissues from chemotherapy-induced damage, and reduce toxicity for the patient. However, repopulation of surviving tumor cells between therapy cycles is commonly observed. Moreover, accelerated rates of regrowth after successive treatments have been reported, potentially fueling resistance that is often observed after an initial response. 90, 91 Tumor repopulation in the so-called drug holidays may, at least in part, be due to host processes activated by chemotherapy. To avoid this, chemotherapy can be administered in a metronomic schedule. 37 Frequent administration prevents regrowth in between cycles and low doses cause less damage to the microenvironment, potentially minimizing the host response. In fact, metronomically administered chemotherapy has been shown to prevent the CEP surges into the circulation that were observed when administering the same cytotoxic agent at its maximum-tolerated dose. 92 Co-administration of low-dose chemotherapy to a vascular disrupting agent was also able to block the vascular disrupting agent-induced CEP spikes. 88 Tumors that have acquired resistance to maximum-tolerated dose chemotherapy were still found to be sensitive to the same drug when it was metronomically administered, and vice versa. 35, 36, 93 In addition, the use of a 'chemo-switch' regimen in which maximum-tolerated dose chemotherapy is followed by a metronomic regimen has been shown to effectively inhibit tumor regrowth or resistance to therapy. 94 Metronomic chemotherapy has been evaluated in several non-randomized phase 2 clinical trials, 95, 96 as well as in a randomized phase 2 setting involving metronomic cyclophosphamide with aromatase inhibitors. 97 Promising activity has been shown, along with favorable toxicity profiles. 98, 99 Several phase III clinical trials are currently ongoing. In addition, one could argue that adjuvant trials using daily non-toxic doses of the 5-FU oral prodrug UFT in non-small cell lung cancer and breast cancer represent examples of successful metronomic chemotherapy-like regimens in phase III. 100, 101 Another method of minimizing host responses is by attempting to make chemotherapy more tumor-specific, for example, by coupling chemotherapy to specific transporters or by making hypoxia prodrugs. 102 However, it will be very difficult to completely abrogate the effects of chemotherapy on healthy tissues. An alternative approach is to use a combination of a cytotoxic agent targeting the tumor and an agent that interferes with the evoked host response. A number of strategies can be followed, such as targeting protumorigenic cytokines released in response to therapy, targeting recruitment and homing of BMDCs, or targeting downstream pathways within BMDCs or stromal cells in the microenvironment (Table 1) . Preclinically, all of these approaches have been used with considerable success. Direct inhibition of the SDF-1/CXCR-4 axis prevented the chemotherapyinduced CEP spike. 45 Targeting the VEGF/VEGFR pathway had similar effects, and the synergism of combining chemotherapy with antiangiogenic agents has been extensively studied. 103 Clinically, bevacizumab is approved in combination with cytotoxic agents for patients with advanced colorectal cancer, non-small cell lung cancer, and in Europe also for advanced breast cancer and ovarian cancer. Examples of targeting downstream pathways in stromal cells are the use of COX-1 and TXS inhibitors to prevent PIFA release from MSCs, 75 and JAK-2/3 or p38 blockade in thymic endothelial cells to prevent local survival of tumor cells. 78 Additionally, when a large quantity of factors is released following chemotherapy, which is the case in DDSP, interfering with the paracrine interactions will be most efficient by targeting master regulators in stromal cells. In fibroblasts, these include NF-kB, p38-MAPK or PARP-1.
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DISCUSSION
The host response can be seen as an attempt of the body to protect tissues crucial for its well-functioning and homeostasis, which is exploited by the tumor. MSCs, for example, are recruited to wounds and other sites of injury, where they contribute to tissue repair. The massive damage exerted to a tumor by chemotherapy might elicit a similar response in the MSCs, thereby aiding tumor repopulation. Similarly, CEP recruitment to tumors may be aimed at repairing the damage provoked by vascular disrupting agent or chemotherapy, and acute cell stress can trigger the DDSP and senescence-associated secretory phenotype. Therefore, a challenge in interfering with the host response is to maintain its important physiological role in tissue repair of healthy tissues while preventing repair in malignant tissues. If the balance swings too much towards allowing repair, tumors may benefit. However, if too much weight is put on preventing repair, the patient might experience numerous side effects.
An important question that needs to be addressed clinically is whether the host responses described above occur in all patients, or whether a subset is more at risk. We know that some patients respond better to chemotherapy than others, and some patients experience more side effects than others. Despite the use of predictive models, it is presently hard to select the patients who will benefit most from therapy, nor patients who will suffer most. Albeit speculative, there may also be subsets of patients that generate a stronger or differential host response. Additionally, a large spectrum of responses including numerous (bone marrowderived) cell types and signaling cascades has been reported, and different patients will likely suffer from different responses. The host response to therapy will depend on the nature of the microenvironment, which is dynamic and influenced by the drug used. Also tumor type, localization, stage and treatment will affect the host response, as well as the characteristics of individual patients and tumors. Despite these challenges, we believe that further research should be focused on the combination of conventional antitumor therapies with interventions specifically aimed at preventing the host response. A better understanding of the host responses to anticancer treatment, and the crucial role these effects can have in therapy outcome, has the potential to significantly improve cancer therapy. Taylor et al. 65 Daenen et al.
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Elevations of SDF-1 and recruitment of TEMs to tumors Interfering with the SDF-1/CXCR-4 pathway
Welford et al.
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Abdominal surgery
Changes in numerous pro-anigogenic cytokines and recruitment of CECs and CEPs
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Recruitment of CD11b-expressing myeloid cells Antibodies to Mac1 (CD11b/CD18) Ahn et al.
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Recruitment multiple protumorigenic cytokines and CCR2-expressing mesenchymal stem cells
Inhibition of CCR2 Klopp et al.
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Abbreviations: BMDCs, bone marrow-derived cells; CEC, circulating endothelial cells; CEP, circulating endothelial progenitor cells; TAM, tumor-associated macrophages; TEM, Tie2-expressing monocytes; VDA, vascular disrupting agent.
